Home    Back

Epicatechin    (DrugBank: Epicatechin)

2 diseases
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension1
113Muscular dystrophy4

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1,083 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01880866
(ClinicalTrials.gov)		July 201328/5/2013(-)-Epicatechin and Pulmonary Arterial HypertensionAn Open Label Pilot Study of Purified (-)-Epicatechin to Improve Hemodynamics in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: (-)-EpicatechinUniversity of California, San FranciscoNULLWithdrawn18 YearsN/ABoth0Phase 1United States

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 567 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04386304
(ClinicalTrials.gov)		July 13, 20201/5/2020Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular DystrophyA Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Orally Administered (+)-Epicatechin in Patients With Becker or Becker-like Muscular Dystrophy With Continued Ambulation Past 16 Years of AgeBecker Muscular DystrophyDrug: (+)-EpicatechinEpirium Bio Inc.NULLRecruiting16 Years59 YearsMale20Phase 1United States
2NCT03236662
(ClinicalTrials.gov)		November 20167/11/2016(-)- Epicatechin Becker Muscular DystrophyUCD0115B: An Open-label Extension Study of Purified Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular DystrophyBecker Muscular DystrophyDrug: (-)-EpicatechinCraig McDonald, MDCardero Therapeutics, Inc.Completed18 Years70 YearsMale10Phase 2United States
3NCT02964377
(ClinicalTrials.gov)		November 20167/11/2016Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory AdolescentsA Single Center Dose Ranging Pilot Study of (+)-Epicatechin in Non-ambulatory Adolescents With Duchenne Muscular Dystrophy and Pre-symptomatic Cardiac DysfunctionDuchenne Muscular DystrophyDrug: (+)- EpicatechinCraig McDonald, MDCardero Therapeutics, Inc.Completed8 Years17 YearsMale15Phase 1;Phase 2United States
4NCT01856868
(ClinicalTrials.gov)		May 20139/5/2013Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.Becker Muscular DystrophyDrug: (-)-epicatechinCraig McDonald, MDCardero Therapeutics, Inc.Completed18 Years60 YearsMale7Phase 1;Phase 2United States

Back to top